Inhalation Sciences to present at FDA’s public workshop GDUFA on May 20th, 2024
Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic Drug User Fee Amendments) on May 20th, 2024.
The annual GDUFA Public Workshop is open and free to the public, and any member of the public may provide comments to the docket for the meeting or may provide their public comments in a prepared presentation, or as impromptu comments. The FDA routinely announces the workshop and provides information about how the public may provide comments. This includes information about how the public can submit a request to provide a public comments presentation.
The topic of the session is “Predictive Tools for Generic Product Development & Assessment” and ISAB’s presentation will be held by the company’s founder and Chief Scientific Officer Per Gerde.
ISAB CEO Manoush Masarrat: “We are very pleased to be invited by the FDA and we really look forward to discussing the challenges for generic product development and assessment! ISAB is increasingly gaining a reputation as a leading innovator and provider of Inhalation Research Services, offering a broad range of services within this field”.
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enabling researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
Tags: